Targeted Radiolabeled Compounds in Glioma Therapy
- 1 May 2016
- journal article
- review article
- Published by Elsevier BV in Seminars in Nuclear Medicine
- Vol. 46 (3), 243-249
- https://doi.org/10.1053/j.semnuclmed.2016.01.009
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 casesJournal of Neurosurgery, 2013
- Decay data measurements on 213Bi using recoil atomsApplied Radiation and Isotopes, 2013
- IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survivalNeuro-Oncology, 2013
- Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and StrategiesAnnual Review of Chemical and Biomolecular Engineering, 2011
- Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance PClinical Cancer Research, 2006
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001Neurosurgical Focus, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- A 25 year adventure in the field of tachykininsPeptides, 2004
- Substance‐P receptors in human primary neoplasms: Tumoral and vascular localizationInternational Journal of Cancer, 1995